Could RenovoRx be building a stronger medtech oncology moat through global patent expansion?
Could RenovoRx’s Japan patent strengthen the RenovoCath oncology moat? Read the full PDN analysis on commercial risks, adoption, and global expansion.
ESMO-EURACAN adds CHEMOSAT to uveal melanoma guidance as Delcath Systems strengthens clinical position
Delcath Systems won ESMO-EURACAN guideline recognition for CHEMOSAT in uveal melanoma. Read what this could change for liver-directed cancer care.
Delcath subgroup data links survival to tumor burden and LDH in uveal melanoma
New Phase 3 subgroup data suggest Delcath’s HEPZATO KIT improves survival in patients with lower tumor burden or LDH. Learn what this means for mUM treatment.
Can Delcath’s HEPZATO redefine the treatment window for metastatic uveal melanoma?
New subgroup data on HEPZATO highlights improved survival in low-burden metastatic uveal melanoma. Find out what this changes in clinical strategy.
Why the MiRaDoR study may redefine therapeutic timing in HR+/HER2- patients
Natera Inc. and Medica Scientia Innovation Research (MEDSIR) have announced a collaborative effort on the MiRaDoR study, a multicenter, phase II clinical trial focused on hormone receptor-positive, HER2-negative (HR+/HER2-) breast cancer. Sponsored by MEDSIR and funded by F. Hoffmann-La Roche Ltd., the trial uses Natera’s Signatera assay to guide therapy decisions based on circulating tumor […]